FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price

First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat Topline results expected in fourth quarter of 2020 FOSTER CITY, Calif. , July 9, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of

Late breaker presentation of long-term analysis of Phase 2 INDIGO study shows sustained response and clinically-relevant growth accelerations in PFIC2 responders Data from Phase 2b ICONIC study show profound and durable improvements in itch severity and serum bile acids in children with Alagille

Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two

Mike Grey to Remain with Mirum in Role of Executive Chairman FOSTER CITY, Calif. , March 21, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the appointment of Chris Peetz as chief executive officer. The company's former CEO, Mike Grey , will stay on with Mirum in the role of executive